SciELO - Scientific Electronic Library Online

 
vol.15 número2Nanorradiolipossomas modulados molecularmente para estudar a drenagem linfática pulmonar profundaExacerbação aguda da fibrose pulmonar idiopática índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Portuguesa de Pneumologia

versão impressa ISSN 0873-2159

Rev Port Pneumol v.15 n.2 Lisboa mar. 2009

 

Teste tuberculínico. Como optimizar?

 

Raquel Duarte 1

 

 

Resumo

Os testes utilizados no diagnóstico de infecção latente pelo Mycobacterium tuberculosis, o teste tuberculínico e o doseamento do interferão gama (IGRA) identificam a existência de uma resposta imunológica adaptativa de memória contra os antigénios micobacterianos. Considerando as limitações dos dois testes, a melhor solução passa por tirar proveito das melhores características de cada um. A maior parte dos autores concorda com a utilização dos dois testes, utilizando os IGRA sobretudo na confirmação da positividade do teste tuberculínico (tirando proveito da sua maior especificidade).

As características operativas do teste tuberculínico dependem da prevalência da doença na comunidade e dos objectivos da sua realização (as suas características são superiores quando utilizada no âmbito de rastreio ou como teste diagnóstico). Para interpretar correctamente um teste tuberculínico, o clínico deve conhecer a epidemiologia da tuberculose na comunidade e definir correctamente as indicações para a sua realização.

Palavras-chave: Tuberculose, teste tuberculínico, Mantoux.

 

 

Tuberculin skin test. How to optimise?

Abstract

The tests used in the diagnosis of tuberculosis latent infection, the tuberculin skin test (TST) and the interferon -gamma assays (IGRA), identify the existence of an adaptive immune response towards mycobacterial antigens. Considering the limitations of the two tests, the best solution is to take advantage of the best characteristics of each one. Most of the authors agree to the use of the two tests, using the IGRAS in the confirmation of a positive TST (because of its higher specificity). The operative characteristics of TST depend on the prevalence of the illness in the community and the aim of its use (its operative characteristics are higher when used in the tracing scope or as a diagnostic test). To interpret correctly a TST, the physician must know the epidemiology of tuberculosis in the community and correctly define the indications for its use.

Key-words: Tuberculosis, tuberculin skin test, Mantoux.

 

 

Texto completo disponível apenas em PDF.

Full text only available in PDF format.

 

 

Bibliografia

1. Edwards P, Edwards L. Story of the tuberculin test. Am Rev of Resp Dis 1960; 81:1 -49.        [ Links ]

2. ATS/CDCP (American Thoracic Society/Center for Dis Control and Prevention). Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161:S221 -S247.

3. Bass J. The tuberculin skin test. Am Rev Resp Dis 1990; 142:24 -28.

4. Bass J. The tuberculin test. In: Reichman L, Hershfield E (eds). Tuberculosis: a comprehensive international approach. Marcel Dekker, New York, 1993.

5. Berkel GM, Cobelens FG, et al. Tuberculin skin test: Estimation of positive and negative predictive values from routine data. Int J Lung Dis 9 (3):310 -316.CDC.

6. MMWR Morb Mortal Wkly Rep 2000. Disponível em http://www.cdc.gov/mmwr.

7. Reichler MR, Reves R, Bur S, Thompson V, Mangura BT, Ford J, Valway SE, Onorato IM. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002: 287(8): 991 -995.

8. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 2000: 55(11): 887 -901.

9. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow -up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982: 60(4): 555 -564.

10. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Database System Rev 2005 (4). Disponível em http://www.cochrane/clsysrev

11. Mazurek G, Villarino M, et al. Guidelines for using the quantiferon -TB Test for diagnosing latent Mycobacterium tuberculosis infection. Recommendations and Reports. MMWR 2003; 52 (No. RR -2):15 -19. Disponível em http://www.cdc.gov/mmwr.

12. Pai M, Riley L, et al. Interferon gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet 2004; 4:761 -775.

13. Reichman L, Lambregts K, et al. Guidelines for the diagnosis of latent tuberculosis infection for the 21st century. New Jersey Medical Scholl. National tuberculosis Center 2004.

14. Barnes P. Diagnosing latent tuberculosis infection. Turning glitter to gold. Am J Respir Crit Care Med 2004; 170:5 -6.

15. Ewer K, Deeks J, et al. Comparison of T -cell –based assay with tuberculin skin test for diagnosis of Mycobacterium infection in a school tuberculosis outbreak. Lancet 2005; 361:1168 -1173.

16. Gokhale P, Dogra J. Mycobacterium tuberculosis infection in health care workers in rural India: comparison of a whole -blood interferon gamma assay with tuberculin skin testing. JAMA 2005; 293 (22):2746 -2747.

17. Kang YA, Lee H, et al. Discrepancy between the tuberculin skin test and the whole -blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis -burden country. JAMA 2005; 293 (22):2785 -2787.

18. Pai M, et al. Mycobacterium tuberculosis infection in health care workers in rural India. Comparison of a whole blood interferon gamma assay with tuberculin skin testing. JAMA 2005; 293 (22):2746 -2755.

19. Pai M. Interferon assays for tuberculosis. Is anergy the Achiles'heel? Am J Resp Crit Care Med 2005; 172:519 -520.

20. Ridzon R. Optimal latent TB control methods. Int J Tuberc Lung Dis 9 (3):236.

21. Lalvani A, Millington KA. T cell -based diagnosis of childhood tuberculosis infection. Curr Opin Infect Dis 2007: 20(3): 264 -271.

22. Magnusson M and Bentzon MW. Preparation of purified tuberculin RT -23. Bull WHO 1958; 19:829-  43.

23. World Health Organization. The WHO standard tuberculin test. WHO/TB/Technical Guide/3.22 February 1963.

24. Davies PDO and Leitch AG. Practical problems of tuberculin test. In: Davies PDO (Ed.). Clinical Tuberculosis, Chapman & Hall, London 1944:345 -9.

25. Arnadottir T, Rieder HL, Trebucq A, Waller HT. Guidelines for conducting tuberculin skin test surveys in high prevalence countries. Tubercle Lung Dis 1996;77 (Suppl): 1 -20.

26. Rose DN, Schechter CB, Adler JJ. Interpretation of the tuberculin skin test. J Gen Intern Med 1995; 10(11):635 -42.

27. Kapoor RK, Wakhlu I, Gupta PK, Saksena PN. Diagnostic utility of BCG test in children. J Indian Medical Ass 1982;78: 177 -80.

28. Bhandari NR, Bhambal SS, Beohar V. Diagnostic value of BCG test in childhood tuberculosis. Indian Pediatrics 1984;21: 555 -9.

29. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974: 99(2): 131 -138

30. Vynnycky E, Fine PE. Lifetime risks, incubation period, and serial interval of tuberculosis. Am J Epidemiol 2000: 152(3): 247 -263

31. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989: 320(9): 545-550.

32. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, Miro JM, Mallolas J, Zamora L, Gonzalez J, et al. A prospective study of the risk of tuberculosis among HIV -infected patients. Aids 1993:7(10): 1345 -1349.

33. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV -infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995: 274(2): 143 -148.

34. Programa Nacional de Luta Contra a Tuberculose – Sistema de Vigilância (SVIG -TB). Ponto da situação epidemiológica e indicadores de desempenho. Ano 2006 Direcção-Geral de Saúde. Divisão de Doenças Transmissíveis.

 

1 Assistente Hospitalar de Pneumologia

 

Recebido para publicação/received for publication: 08.09.29

Aceite para publicação/accepted for publication: 08.11.10